Bruker Corporation
BRKR
Helyezés a részvények között
#2369
Bruker Corporation stands as a prominent global developer, manufacturer, and... Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
Részvényárfolyam
$54.54
Utolsó szinkronizálás: 2026-10-16
Piaci kapitalizáció
$8.31B
Változás (1 nap)
-3.55%
Változás (1 év)
47.47%
Ország
US
Kereskedés Bruker Corporation (BRKR)
Kategória
Healthcare
Működési árrés a(z) Bruker Corporation (BRKR) esetén
Működési árrés ekkor: October 2026 TTM: 3.61%
Bruker Corporation legfrissebb pénzügyi jelentései és részvényára alapján a jelenlegi működési árrés (TTM) 3.61%. 2023 végén a működési árrés 14.74% volt.
Működési árrés története a(z) Bruker Corporation esetén 2000 és 2026 között
Működési árrés az év végén
| Év | Működési árrés | Változtassa meg |
|---|---|---|
| 2026 (TTM) | 3.61% | -51.99% |
| 2024 | 7.52% | -48.98% |
| 2023 | 14.74% | -13.80% |
| 2022 | 17.10% | 0.06% |
| 2021 | 17.09% | 36.83% |
| 2020 | 12.49% | -13.98% |
| 2019 | 14.52% | 4.91% |
| 2018 | 13.84% | 13.82% |
| 2017 | 12.16% | 10.55% |
| 2016 | 11.00% | 22.63% |
| 2015 | 8.97% | 53.86% |
| 2014 | 5.83% | -27.67% |
| 2013 | 8.06% | -7.46% |
| 2012 | 8.71% | -7.54% |
| 2011 | 9.42% | -21.04% |
| 2010 | 11.93% | -2.77% |
| 2009 | 12.27% | 25.59% |
| 2008 | 9.77% | 7.01% |
| 2007 | 9.13% | 29.69% |
| 2006 | 7.04% | 97.20% |
| 2005 | 3.57% | -1,015.38% |
| 2004 | -0.39% | -89.49% |
| 2003 | -3.71% | -175.10% |
| 2002 | 4.94% | 39.94% |
| 2001 | 3.53% | 267.71% |
| 2000 | 0.96% | 0.00% |
Működési árrés hasonló cégeknél vagy versenytársaknál
| Vállalat | Működési árrés | Működési árrés különbség | Ország |
|---|---|---|---|
| 17.03% | -95.28% |
US
|
|
| 17.86% | -95.05% |
IE
|
|
| 22.03% | -93.90% |
US
|
|
| 21.46% | -94.06% |
US
|
|
| 0.00% | - |
DE
|
Mi az a vállalat működési árrése?
A működési árrés kulcsfontosságú mutató egy vállalat jövedelmezőségének értékeléséhez. A magasabb működési árrés általában jobb, mivel azt mutatja, hogy a vállalat a termékeit vagy szolgáltatásait jóval a gyártási költség felett tudja értékesíteni. A működési árrés úgy számítható ki, hogy a vállalat nyereségét elosztjuk a bevételével.